N E W S B Y T E S
Aragen operationalizes first phase of its biologics manufacturing facility in India
Miltenyi Biotec opens its first office in India , plans to invest in Cell & Gene Therapy Center of Excellence
Miltenyi Biotec is launching operations in India with its first office and investing to set up Miltenyi Innovation and Technology Center as CGT Centre of Excellence ( COE ) in Hyderabad , India . This COE will be one of its first of its kind in India where scientists , researchers , industry experts , and clinicians can get classroom to hands-on trainings on cell and gene therapy ( CGT ) approaches right from proofof-concept to pre-clinical , clinical development and commercialization . This COE also will provide Indian researchers , scientists and clinicians easier access to expertise , research , and manufacturing solutions . This pivotal platform CliniMACS Prodigy ® is uniquely positioned for end-to-end clinical development to manufacturing of CGT in an automated and functionally closed system for small-large scale manufacturing .
Aragen , a leading Contract Research Development and Manufacturing Organization ( CRDMO ) for small molecules and biologics , has operationalized the first phase of its biologics manufacturing facility in Bangalore , India through its 100 % subsidiary , Aragen Biologics . The facility is being set up at an investment of USD 30 million . It has also executed its first small-scale manufacturing project for a US-based organization for manufacturing a novel anticancer monoclonal antibody ( mAb ). The non-GMP facility can undertake batch sizes upto 50 Litres and includes process development and analytical labs to support the manufacturing activities .
Commenting on the occasion , Manni Kantipudi , CEO Aragen Life Sciences and Director of Aragen Biologics said , “ We are happy to announce the commissioning of the first phase of our biologics manufacturing facility at Bangalore , India as per schedule and the successful completion of the first project at this facility .”
08
BioVoiceNews | May / June 2024